Anciens séminaires 2010-2017

Liste complète des anciens séminaires 2010-2014 :  angry     2015 :  pdf     2016 :  pdf     2017 :  pdf

Mardi 12 Juin 2018, 14h00

Julien Faget


ISREC/EPFL, Lausanne, Suisse


"Learning from models of immunotherapy resistant lung cancer"



Vendredi 8 Juin 2018, 14h00

Roberto Ronca


Department of Molecular and Translational Medicine, University of Brescia

"Stromal delivery of long Pentraxin-3 impairs FGF/FGFR-dependent tumor growth and metastasis"


Summary of the work: 

The fibroblast growth factor (FGF)/FGF receptor (FGFR) system plays a crucial role in cancer by affecting tumor growth, angiogenesis, drug resistance and escape from anti-angiogenic anti-vascular endothelial growth factor therapy. The soluble pattern recognition receptor long-pentraxin 3 (PTX3) acts as a multi-FGF antagonist. In a recent study we demonstrated that local and systemic delivery of human PTX3 in transgenic mice driven by the endothelial specific Tie2 promoter inhibits tumor growth, angiogenesis and metastasis in heterotopic, orthotopic and autochthonous FGF-dependent tumor models. Moreover, NMR data and pharmacophore modeling of the interaction of a minimal PTX3-derived FGF-binding pentapeptide with FGF2 were used for the identification of the first small molecule chemical (NSC12) which acts as an orally active extracellular FGF trap with significant implications in cancer therapy. We are currently characterizing the role of PTX3 expression in different types of solid and hematological tumors.



Vendredi 18 Mai 2018, 14h00

Han Li


Cellular Plasticity and Disease Modelling Group, Institut Pasteur, Paris


"Cellular plasticity in cancer and ageing"


Webmore information


Contact: antonio.maraver@inserm.fr

Vendredi 27 Avril 2018, 14h00

William Ritchie


Head of Artificial Intelligence and Gene Regulation, IGH, Montpellier


“Artificial Intelligence empowers transcriptomics but will ultimately cause its demise"


The seminar in short:

In my talk, I will show how simple information theory concepts such as entropy and information content allow scientists to better understand gene regulation in numerous types of disease. I will then demonstrate that recent advances in artificial intelligence approaches such as genetic programming and neural nets may be so powerful that they abrogate our need to understand these functions at all. Recent research in my team will show how AI allows us to explore sequencing data from cancer samples with no a priori and is more powerful than current approaches for classifying and predicting outcomes.


Contact: charles.theillet@inserm.fr

Vendredi 20 Avril 2018, 14h00

Mickael Ploquin,


10x Genomics


"Single cell transcriptomics and proteomics"




Résumé de la présentation :  High-throughput, single-cell expression measurements enable discovery of gene expression dynamics for profiling individual cell types. The Chromium Single Cell Controller which is a dedicated instrument for single cell applications and features a simple and comprehensive workflow, enabling users to quickly and easily prepare single cell sequencing libraries in less than one workday.


With the unique ability to interrogate hundreds to millions of cells, the Single Cell Chromium Controller supports a variety of applications, including the existing Chromium™ Single Cell 3’ Solution, as well as a future product featuring to perform full-length sequencing of V(D)J segments from single B or T cells. The system is accompanied by Chromium Single Cell 3’ Reagent Kits with advanced chemistry and microfluidics consumables based on GemCode™ Technology and features full compatibility with the Illumina® HiSeq® 4000 and other HiSeq®, NovaSeq®, NextSeq® and MiSeq® sequencers.

Jeudi 29 Mars 2018, 14h00

Max Chaffanet


Département d’Oncologie Moléculaire Institut Paoli Calmettes, Marseille


“Profilage oncogénomique des cancers avancés dans les essais PANDORA et PERMED à l’IPC"


Contact: charles.theillet@inserm.fr

Vendredi 9 Février 2018, 14h00

Sylvain Lehmann et Brigitte Couette


Projet IBDLR (Initiative Biomarqueurs et Diagnostic en Languedoc-Roussillon), BioCampus, Montpellier


"Présentation de l’ (IBDLR) : Actions et Appel à candidature "Labellisation de projets Biomarqueurs" 


Contact: charles.theillet@inserm.fr


Bref résuméL’objet de cette présentation, qui s’inscrit dans une démarche systématique auprès des différents Instituts/laboratoires, est de faire connaître notre initiative qui a pour vocation de faciliter l’émergence et la validation de nouveaux Biomarqueurs en accompagnant les chercheurs sur le chemin de la valorisation économique de leurs activités de recherche.

IBDLR sert d’interface entre les laboratoires de recherche et les structures de valorisation : https://www.polebiosante-rabelais.fr/polerabelais/projets-structurants/ibdlr

Ses missions :
  • Faciliter l’émergence et la validation de nouveaux Biomarqueurs
  • Apporter son expertise pour accompagner les projets vers un niveau de maturité technologique pour une prise en charge par les acteurs régionaux de la valorisation
  • Décerner un label pour les projets ayant des perspectives pouvant intéresser des industriels
  • Financer des équipements performants pour la validation des Biomarqueurs (CPER-IBDLR)
  • Organiser des évènements autour des Biomarqueurs

© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés